Literature DB >> 25618611

Appropriate use of vancomycin in a pediatric emergency department through the use of a standardized electronic guideline.

Sarah Likis Powell1, Erica Liebelt2.   

Abstract

OBJECTIVES: (a) Compare utilization of vancomycin in the ED prior to and after implementation of standardized treatment guideline and order template (STGOT); (b) assess the appropriate use as initial therapy based on indication versus admitting diagnosis.
METHODS: Chart audits on all patients who received vancomycin and were admitted. Overall utilization and appropriateness of starting therapy were compared pre-and post-STGOT implementation.
RESULTS: Overall utilization of vancomycin was 4% pre-STGOT compared to 3% post-STGOT; 98% of patients pre-STGOT compared to 99% post-STGOT received vancomycin appropriately.
CONCLUSION: There was no difference in vancomycin utilization and appropriateness of initiating therapy after STGOT implementation.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Electronic guideline; Pediatric emergency department; Vancomycin

Mesh:

Substances:

Year:  2015        PMID: 25618611     DOI: 10.1016/j.pedn.2014.12.014

Source DB:  PubMed          Journal:  J Pediatr Nurs        ISSN: 0882-5963            Impact factor:   2.145


  3 in total

1.  A new approach to Vancomycin utilization evaluation: A cross-sectional study in intensive care unit.

Authors:  Atefeh Mahmoodian; Saeed Abbasi; Shadi Farsaei
Journal:  J Res Pharm Pract       Date:  2016 Oct-Dec

2.  Evaluation of vancomycin use in university-affiliated hospitals in Southern Khorasan Province (East Iran) based on HICPAC guidelines.

Authors:  Motahare Mahi-Birjand; Masood Ziaee; Bita Bijari; Reza Khalvati; Mohammad Reza Abedini; Hasan Golboei Mousavi; Arash Ziaee
Journal:  Drug Healthc Patient Saf       Date:  2019-04-08

Review 3.  Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review.

Authors:  D Donà; E Barbieri; M Daverio; R Lundin; C Giaquinto; T Zaoutis; M Sharland
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-03       Impact factor: 4.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.